Genetic regulation of ALK inhibitor response in diverse human cell types

Anaplastic lymphoma kinase (ALK) inhibitors are effective treatments for ALK-positive non-small cell lung cancer but cause diverse adverse events affecting multiple tissues. Genetic variation may contribute to inter-individual differences in susceptibility, but the small number of treated patients limits the power of genetic association studies. Moreover, the diversity of affected tissues and cell types makes functional investigation challenging. We used induced pluripotent stem cells from 49 individuals to generate heterogeneous differentiating cultures (HDCs) containing multiple cell types, treated them with five ALK inhibitors (crizotinib, alectinib, ceritinib, brigatinib, and lorlatinib) for 24 hours, and characterized transcriptional responses using single-cell RNA sequencing. These responses showed cell-type-specific and shared transcriptional effects. Integrating gene expression with individual genotypes, we identified 4,371 expression quantitative trait loci (eQTLs) across 21 cell types, including 2,137 response eQTLs whose regulatory effects differ between untreated and drug-treated cells. These results nominate candidates for future studies of ALK inhibitor toxicity.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-17
DOI
https://doi.org/10.64898/2026.11.16.766986
Primary Topic
Lung Cancer Treatments and Mutations
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Genetic regulation of ALK inhibitor response in diverse human cell types

Yoav Gilad, Katherine Rhodes, Natalia M. Gonzales, Kenneth Barr et al.
1 links
bioRxiv (Cold Spring Harbor Laboratory)
Lung Cancer Treatments and Mutations
preprint

Genetic regulation of ALK inhibitor response in diverse human cell types

Yoav Gilad, Katherine Rhodes, Natalia M. Gonzales, Kenneth Barr, Elizabeth Geena Woo, Everett E. Vokes, Emaan Mohsin
preprint en

Abstract

Anaplastic lymphoma kinase (ALK) inhibitors are effective treatments for ALK-positive non-small cell lung cancer but cause diverse adverse events affecting multiple tissues. Genetic variation may contribute to inter-individual differences in susceptibility, but the small number of treated patients limits the power of genetic association studies. Moreover, the diversity of affected tissues and cell types makes functional investigation challenging. We used induced pluripotent stem cells from 49 individuals to generate heterogeneous differentiating cultures (HDCs) containing multiple cell types, treated them with five ALK inhibitors (crizotinib, alectinib, ceritinib, brigatinib, and lorlatinib) for 24 hours, and characterized transcriptional responses using single-cell RNA sequencing. These responses showed cell-type-specific and shared transcriptional effects. Integrating gene expression with individual genotypes, we identified 4,371 expression quantitative trait loci (eQTLs) across 21 cell types, including 2,137 response eQTLs whose regulatory effects differ between untreated and drug-treated cells. These results nominate candidates for future studies of ALK inhibitor toxicity.

bioRxiv (Cold Spring Harbor Laboratory)
Northwestern University (US), University of Chicago (US), University of Chicago Medicine Comprehensive Cancer Center (US)
Cancer Research Foundation
Good health and well-being
Lung Cancer Treatments and Mutations
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon